Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2012-09-20EMA Withdrawn: Rasitrio (aliskiren;amlodipine;hydrochlorothiazide) — Novartis Europharm Ltd.
EMA has withdrawn Rasitrio (aliskiren; amlodipine; hydrochlorothiazide) from the market for hypertension.
-
EMA withdrawal · 2012-09-20EMA Withdrawn: Riprazo HCT (aliskiren;hydrochlorothiazide) — Novartis Europharm Ltd.
EMA withdrew Riprazo HCT (aliskiren and hydrochlorothiazide) from the market.
-
EMA withdrawal · 2012-08-28EMA Withdrawn: Sprimeo HCT (aliskiren;hydrochlorothiazide) — Novartis Europharm Ltd.
The EMA withdrew Sprimeo HCT (aliskiren and hydrochlorothiazide) from the market.
-
EMA withdrawal · 2012-07-23EMA Withdrawn: Sprimeo (aliskiren) — Novartis Europharm Ltd.
EMA withdrew Sprimeo (aliskiren) from the European market.
-
CLINICAL_TRIALS withdrawal · 2012-07-16Clinical Trial Update: Does Administration of Etomidate and Propofol of the Anesthetic Induction of Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngoscopy When Compared to Propofol or Etomidate Alone? [Phase 3]
A Phase 3 trial evaluating whether combining etomidate and propofol provides better blood pressure stability during direct laryngoscopy in e…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2012-07-06Clinical Trial Update: Effect of Eplerenone in Elderly Hypertensive Early Stage Chronic Kidney Disease (CKD) Patients [Phase 4]
A Phase 4 trial evaluating eplerenone for elderly patients with hypertension and early-stage chronic kidney disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-07-06Clinical Trial Update: Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension [Phase 2, Phase 3]
Phase 2/Phase 3 trial evaluating losartan on retinal endothelial function in patients with essential hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-04-06Clinical Trial Update: Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab [NA]
A clinical trial comparing nebivolol to lisinopril for new-onset or bevacizumab-induced hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2012-03-16Clinical Trial Update: A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension [Phase 2]
A Phase 2 randomized, double-blind, placebo-controlled trial of Cardene I.V. for pediatric hypertension was withdrawn from the study. No res…
-
CLINICAL_TRIALS withdrawal · 2012-03-06Clinical Trial Update: Comparison of Amlodipine and Aliskiren in Diabetic Hypertensive Patient With Blood Pressure Not Controlled by Losartan [Phase 4]
A Phase 4 trial comparing amlodipine and aliskiren in diabetic patients with hypertension not controlled by losartan has been withdrawn. The…
-
CLINICAL_TRIALS withdrawal · 2012-01-26Clinical Trial Update: Role of Enhanced External Counterpulsation (EECP) Therapy in Patients With Resistant Hypertension [NA]
This clinical trial update reports that a study evaluating enhanced external counterpulsation (EECP) therapy for resistant hypertension has …
-
CLINICAL_TRIALS withdrawal · 2012-01-26Clinical Trial Update: Effect of Treating Sleep Disorder Breathing in Patients With Resistant Hypertension [NA]
A clinical trial examining treating sleep-disordered breathing in patients with resistant hypertension has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2011-06-22Clinical Trial Update: Accuracy of Non-Invasive Blood Pressure Measurement in Adults
A clinical trial evaluating the accuracy of a non-invasive blood pressure device in adults has been withdrawn; sponsor is Sotera Wireless, I…
-
EMA withdrawal · 2011-05-19EMA Withdrawn: Enviage (aliskiren) — Novartis Europharm Ltd.
The EMAWithdrawn notice states Enviage (aliskiren) has been withdrawn from the European market for hypertension.
-
EMA withdrawal · 2011-03-02EMA Withdrawn: Thelin (sitaxentan sodium) — Pfizer Ltd.
Thelin (sitaxentan sodium) has been withdrawn from the market by Pfizer Ltd., with a status of Withdrawn in the EMA record.
-
EMA withdrawal · 2009-11-26EMA Withdrawn: Irbesartan BMS (irbesartan) — Bristol-Myers Squibb Pharma EEIG
The EMA withdrew the irbesartan product Irbesartan BMS (irbesartan) from Bristol-Myers Squibb Pharma EEIG, affecting its hypertension therap…
-
EMA withdrawal · 2009-11-24EMA Withdrawn: Irbesartan Hydrochlorothiazide BMS (irbesartan;hydrochlorothiazide) — Bristol-Myers Squibb Pharma EEIG
The EMA withdrawal of irbesartan/hydrochlorothiazide (BMS) from the European market in 2009.
-
EMA withdrawal · 2009-09-25EMA Withdrawn: Tekturna (aliskiren) — Novartis Europharm Ltd.
Tekturna (aliskiren) has been withdrawn from the European market by Novartis Europharm Ltd.